COVID19AM: Development and Phase II clinical trial to demonstrate the efficacy of the neutralising antibody COR-101 for the treatment of hospitalised patients with moderate to severe COVID-19 disease (CORAMAR)
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:0 publications
Grant number: 16LW0107
Grant search
Key facts
Disease
COVID-19Start & end year
20222022Known Financial Commitments (USD)
$6,339,200.51Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
N/A
Research Location
GermanyLead Research Institution
CORAT Therapeutics GmbHResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Clinical trials for disease management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase II
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified